Enrolling by invitationPhase 4
Efficacy and Safety of Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients
Key facts
- Who runs it
- Dow University of Health Sciences
- Where
- Karachi, PakistanSee the site
- Trial code
- Status
- Enrolling by invitation
- Phase
- Phase 4
- People taking part
- 30 people, planned
- Started
- 1 Jan 2025
- Expected to end
- 30 Mar 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Apremilast with NB-UVB
- NB-UVB
- Record updated
- 11 March 2025
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients age 18 years and above
- Patients of both genders (male and female)
- Diagnosed patients of non-segmental vitiligo involving > 5% of BSA
Who cannot take part
- Concomitant active infection like tuberculosis
- Use of phototherapy within 4 weeks before randomization
- Personal history of cutaneous malignancy
- Pregnant and lactating women
- Use of apremilast in the past 4 weeks
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in Pakistan
- Dow International Medical College , DUHSKarachi, PakistanNo longer taking part
About the trial
What the trial wants to find out
Patients of non-segmental vitiligo, fulfilling the inclusion criteria will be selected from the OPD, dermatology department. It\'s an interventional study where Group A patient will be given NBUVB and Tab Apremilast 30 mg twice a day and Group B will receive NBUVB alone.
The 2 groups in the trial
- Apremilast with phototherapyTreatment being tested
- Phototherapy aloneExisting treatment, for comparison
Treatment: NB-UVB
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Comparison Between Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo - a Randomized Controlled Trial
- Fit questions
- Built from NCT06593197, who can take part
- Record updated
- 11 March 2025